AI strengthens grip on low hanging fruit with Exscientia, Dainippon Sumitomo trial start

Exscientia and Dainippon Sumitomo’s trial start for a compound accelerated through preclinical development via AI suggests the technology is starting to deliver on its first promise to drug developers: speeding up the chemistry they already

Read the full 350 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE